Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.49 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.49 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.49 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.49 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.49 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.49 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5097657 | 0.92 | NPSR1 (0.46) | NPC1RAB9AL3MBTL1AGTR2PSEN1 | |
| SCHEMBL14218351 | 0.86 | HTR2C (0.47) | NPC1RAB9AL3MBTL1AGTR2PSEN1 | |
| SCHEMBL2282075 | 0.81 | HTR2C (0.52) | NPC1RAB9AL3MBTL1AGTR2PSEN1 | |
| SCHEMBL17294985 | 0.80 | NPC1 (0.46) | NPC1RAB9AL3MBTL1SMN1; SMN2NPSR1 | |
| SCHEMBL4534787 | 0.80 | AGTR2 (0.50) | NPC1RAB9AAGTR2PSEN1PSEN2 | |
| SCHEMBL9865373 | 0.79 | HDAC1 (0.50) | NPC1RAB9AL3MBTL1AGTR2PSEN1 | |
| SCHEMBL1690517 | 0.79 | NPSR1 (0.56) | NPC1RAB9AL3MBTL1NPSR1HTR2C | |
| SCHEMBL18970283 | 0.79 | NPSR1 (0.56) | NPC1RAB9AL3MBTL1NPSR1HTR2C | |
| SCHEMBL927563 | 0.79 | PSEN1 (0.49) | NPC1RAB9AAGTR2PSEN1PSEN2 | |
| SCHEMBL1052393 | 0.79 | NPSR1 (0.62) | L3MBTL1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371754-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1496907-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1496907-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1496907-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20050227988-A1 | compounds capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases; gliomas, meningomas, cancers, Hodgkin's disease, retinal vascularization; core structure that comprises a benzazocine moiety | MERCK SHARP & DOHME CORP. | 2005-10-13 | — | — | US | disclosed |
| EP-1496907-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003086315-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227988-A1 | compounds capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases; gliomas, meningomas, cancers, Hodgkin's disease, retinal vascularization; core structure that comprises a benzazocine moiety | KDR, RET, FLT1 | NPC1 2550/4885RAB9A 1963/4885L3MBTL1 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.